Patient-reported outcomes as end points and outcome indicators in solid tumours
Cet article passe en revue les travaux récents suggérant l'intérêt d'intégrer des critères de jugement rapportés par les patients, tels que la qualité de vie, dans les essais cliniques de traitements pour les patients atteints d'une tumeur solide
Patient-reported outcome (PRO) measures, such as quality of life, have been associated with relevant clinical end points and are prognostic for survival outcomes in a variety of solid cancers in adults. In the past few years, PROs have garnered a greater influence as established and clinically relevant measures that could alter the current paradigm of practice-changing therapeutic advances, as it has been recognized that classic clinical end points do not accurately portray a full appreciation of the benefits, risks and costs of therapy. In this Review, we comprehensively assess the correlation of PROs with treatment response and survival, and explore tumour-related and patient-centric composite end points in patients with cancer participating in clinical trials. Comparisons or composite end points that consider tumour-related and PRO components might help health-care providers, patients with cancer and decision makers to better understand the total clinical benefit of therapeutic interventions.
Nature Reviews Clinical Oncology , résumé, 2014